Please note: The information displayed on this page might be outdated.
Chondrial Therapeutics: Reverse merged with Zafgen and became Larimar Therapeutics.
Chondrial Therapeutics is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases. Chondrial’s lead compound is CTI-1601, which the Company is developing as a potential treatment for Friedreich’s Ataxia. CTI-1601 is designed to deliver the frataxin protein to the mitochondria of patients with Friedreich’s Ataxia, who, due to a genetic abnormality, are unable to produce this essential protein.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Pre-Clinical Stage
Disease Space
Central Nervous System
Listing
Private
Website:
Profiles:
Address:
150 Monument Road
Suite 207
Bala Cynwyd, PA 19004
United States

Company Participants at Private Company Showcase NYC 2019

  • Carole Ben-Maimon, CEO
  • John Berman, Vice President, Finance and Operations

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.